Nutraceutical on Hyperuricemia

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study will be to evaluate if a nutraceutical containing quercetin, rutin, bromelain and L-carnosine (Uricemin®) can reduce uric acid levels in subjects with values between ≥ 6 and < 7 mg/dl after 3 months of therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pavia
• Treatments: Quercetin

Criteria

Inclusion Criteria:

• Patients with uric acid levels between ≥ 6 and < 7 mg/dl

• Patients not taking hypouricemic agents (both pharmaceuticals or nutraceutical agents)

Exclusion Criteria:

• Patients with previous gout attack

• Patients with impaired hepatic function

• Patient with impaired renal function

• Patients with gastrointestinal disorders

• Patients with current or previous evidence of ischemic heart disease, heart failure, or stroke

• Patients with weight change of > 3 Kg during the preceding 3 months

• Patients with history of malignancy, and significant neurological or psychiatric disturbances, including alcohol or drug abuse.

• Patients taking (within the previous 3 months) hypouricemic agents, laxatives, beta-agonists (other than inhalers), cyproheptadine, antidepressants, antiserotoninergics, phenothiazines, barbiturates, oral corticosteroids, and antipsychotics

• Women who were pregnant or breastfeeding or of childbearing potential and not taking adequate contraceptive precautions.